View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 17, 2020

Inovio gets grant to partner with IVI and KNIH for Covid-19 vaccine

Inovio Pharmaceuticals has received $6.9m in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to collaborate with the International Vaccine Institute (IVI) and the Korea National Institute of Health (KNIH) for a Covid-19 vaccine trial.

Inovio Pharmaceuticals has received $6.9m in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to collaborate with the International Vaccine Institute (IVI) and the Korea National Institute of Health (KNIH) for a Covid-19 vaccine trial.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The alliance is for a Phase I/II trial of Inovio’s vaccine candidate, INO-4800, in South Korea. IVI will perform the trial in parallel with Inovio’s Phase I trial conducted in the US.

The US trial is designed for 40 healthy adults and will later expand to older adults.

IVI director general Dr Jerome Kim said: “The rapid global response to developing vaccine candidates has been a profound demonstration of governments, industry, and the scientific community coming together to confront a common crisis, and we’re looking forward to accelerating one of those candidates through clinical testing.

“IVI has achieved promising trial results with Inovio’s DNA vaccine platform in the past, and we’re pleased to partner again to test the safety and immunogenicity of an urgently needed Covid-19 vaccine.”

The partnership comes after the Korean Ministry of Food and Drug Safety announced on 13 April that the regulator will use a fast-track approval process for Covid-19 vaccine and treatment trials.

Plumbline Life Sciences in South Korea is also partnering on Inovio’s vaccine project.

Korea Centers for Disease Control and Prevention (KCDC) and the KNIH have agreed to support IVI in its testing efforts.

Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “Developing a safe and effective Covid-19 vaccine is a global imperative, and we’re pleased to partner with IVI and KNIH to test INO-4800 in South Korea.

“Our DNA vaccine platform was one of the first technologies to receive support from CEPI to accelerate a Covid-19 vaccine, and IVI conducting safety and efficacy trials in South Korea is a crucial step forward in evaluating this vaccine.”

Inovio’s Covid-19 vaccine candidate is based on its DNA vaccine platform, which was previously used to create MERS vaccine, INO-4700.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena